Abstract: Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome positive chronic-phase chronic myeloid leukemia after failure of interferon.

• 文摘:费城染色体阳性的干扰素治疗失败的处于慢性期的慢性粒细胞白血病患者中的长期存活利益和对imatinib mesylate提升全细胞生成反应及分子反应率的研究。